OverviewSuggest Edit

Dexcom is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. The company provides Dexcom Seven that can show a new glucose reading every five minutes for up to seven days of uninterrupted wear-time.

TypePublic
Founded1999
HQSan Diego, CA, US
Websitedexcom.com
Employee Ratings4.1
Overall CultureD

Latest Updates

Employees (est.) (Dec 2019)3,900(+40%)
Job Openings404
Revenue (FY, 2020)$1.9 B(+31%)
Share Price (Jul 2021)$450.9
Cybersecurity ratingCMore

Key People/Management at Dexcom

Kevin Sayer

Kevin Sayer

Chairman, President & Chief Executive Officer
Quentin Blackford

Quentin Blackford

Chief Financial Officer
Donald Abbey

Donald Abbey

EVP, Quality and Regulatory Affairs
Rick Doubleday

Rick Doubleday

EVP, Chief Commercial Officer
Paul Flynn

Paul Flynn

EVP, Global Revenue
Andrew Balo

Andrew Balo

EVP, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development
Show more

Dexcom Office Locations

Dexcom has offices in San Diego, Brunn am Gebirge, Burnaby, Mainz and in 2 other locations
San Diego, CA, US (HQ)
6340 Sequence Dr
Brunn am Gebirge, AT
Leopold-Gattringer-Straße 25
Burnaby, CA
501 Lougheed Hwy
Mainz, DE
Haifa-Allee 2
Horw, CH
Allmendstr. 18
Camberley, GB
Suite 2.12, Building 3, Watchmoor Park,
Show all (6)

Dexcom Financials and Metrics

Dexcom Revenue

Embed Graph
View revenue for all periods
Dexcom's revenue was reported to be $1.93 b in FY, 2020
USD

Net income (Q1, 2021)

40.3m

EBIT (Q1, 2021)

45.9m

Market capitalization (22-Jul-2021)

43.2b

Closing stock price (22-Jul-2021)

450.9

Cash (31-Mar-2021)

733.8m

EV

44.3b
Dexcom's current market capitalization is $43.2 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

718.5m1.0b1.5b1.9b

Revenue growth, %

44%43%

Cost of goods sold

226.4m367.7m544.5m646.6m

Gross profit

492.1m663.9m931.5m1.3b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

184.4m242.5m266.7m280.5m336.4m396.3m405.1m451.8m500.9m

Cost of goods sold

65.5m88.9m98.1m111.7m129.9m149.4m148.6m167.7m160.5m161.1m

Gross profit

118.9m153.6m168.6m168.8m206.5m246.9m256.5m284.1m340.4m

Gross profit Margin, %

64%63%63%60%61%62%63%63%68%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

441.5m1.1b446.2m817.6m

Accounts Receivable

134.3m226.7m286.3m428.5m

Prepaid Expenses

53.9m

Inventories

45.2m70.7m119.8m234.7m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

420.4m300.2m367.4m1.3b709.2m395.6m584.6m530.0m673.5m733.8m

Accounts Receivable

123.9m162.0m169.8m204.7m217.3m234.9m300.7m296.5m370.0m443.4m

Prepaid Expenses

79.4m

Inventories

51.6m46.2m55.2m101.1m117.9m120.4m141.9m165.3m200.7m289.7m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(50.2m)(127.1m)101.1m493.6m

Depreciation and Amortization

16.1m29.1m48.7m

Inventories

400.0k(25.5m)(49.1m)(114.5m)

Accounts Payable

21.1m56.2m109.0m194.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(24.2m)6.0m52.6m(26.9m)(37.4m)8.4m19.9m66.2m138.4m40.3m

Depreciation and Amortization

6.0m12.7m20.5m9.9m21.5m34.4m13.0m28.3m46.7m20.9m

Inventories

(6.4m)(1.0m)(10.0m)(30.4m)(47.2m)(49.7m)(22.2m)(45.5m)(80.9m)

Accounts Payable

2.2m32.9m50.2m25.5m53.9m78.2m5.3m56.8m126.6m
USDFY, 2017

Revenue/Employee

313.8k

Debt/Equity

0.8 x

Debt/Assets

0.4 x

Financial Leverage

2.2 x
Show all financial metrics

Dexcom Operating Metrics

FY, 2017FY, 2018FY, 2019

Patents (US)

391449516

Patents (Foreign)

424950

Patents Pending (US)

231

Patents Pending (Foreign)

77
Show all operating metrics

Dexcom Acquisitions / Subsidiaries

Company NameDateDeal Size
TypeZero Technologies IncAugust 22, 2018
Nintamed Handels GmbHMay 02, 2016
DexCapital LLC
DexCom Asia Pacific Operations PTE Ltd.
DexCom Canada Co
DexCom (Canada) Inc.
DexCom Deutschland GmbH
DexCom International Ltd.
DexCom Kommanditbolag
DexCom Operating Ltd.
Show more

Dexcom Revenue Breakdown

Embed Graph

Dexcom revenue breakdown by geographic segment: 21.3% from Outside of the United States and 78.7% from United States

Dexcom Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

SecurityScorecard logo

Dexcom Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Dexcom Online and Social Media Presence

Embed Graph

Dexcom Company Culture

  • Overall Culture

    D

    61/100

  • CEO Rating

    C+

    67/100

  • Compensation

    C

    65/100

  • Diversity

    D

    57/100

Learn more on Comparably

Dexcom News and Updates

Worldwide Artificial Pancreas Device Systems Industry to 2026 - Key Players Include Beta Bionics, Dexcom and Insulet Among Others

Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Artificial Pancreas Device Systems (APDS) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global artificial pancreas device systems (APDS) market …

Despite A 23% Rise In A Month Dexcom Stock Will Likely See Higher Levels

Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the last twenty-one trading days. There were some positive developments for the company as well...

Can Dexcom Stock Rebound After The Recent 11% Drop?

While there have been rumors of AppleAAPL coming up with a CGM feature in its Apple Watch, the company hasn’t confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if..

Heads Up Announces Full Integration With Dexcom for Enhanced Continuous Glucose Monitoring

Enables Dexcom users to sync their glucose values onto a single, unified dashboard and share with any healthcare professional.

Can DexCom Stock Gain More After A 10% Rise In Last 5 Days?

The stock price of DexCom, best known for its continuous glucose monitoring systems, has risen by 10% over the last five trading days. Earlier in January, the company reported strong preliminary numbers for Q4, with an estimated top-line growth over 20% y-o-y. The company will report its Q4...

Teladoc Health and Dexcom Bring CGM Technology and Personalized Insights to People with Type 2 Diabetes at No Cost

New offering measures the impact of continuous glucose monitoring and real-time health recommendations for people with Type 2 diabetes New offering measures the impact of continuous glucose monitoring and real-time health recommendations for people with Type 2 diabetes
Show more

Dexcom Blogs

If I am replacing my smart device, what will I need to do?

FAQs Main Categories:  Dexcom G6 CGM System FAQs Sub Categories:  Setting Up Your System Language US - English LBL Number:  LBL021384 Rev001 If you are replacing your smart device and use the Dexcom G6, please review the following instructions. These steps are applicable for only the Dexco…

How do I create a Dependent Account?

FAQs Main Categories:  Follow App for Family & Friends General FAQs Sub Categories:  Using Your Dexcom CGM System Setting Up Your System Language US - English LBL Number:  LBL021379 Rev001 If you are a caregiver of a customer who is under 18 years old, you must create a dependent a…

Apple Watch SE

Device Family:  Apple Watch Version:  Dexcom G6 app watchOS 7.3.2 ||Dexcom Follow app watchOS 7.3.2 Device Enabled: 

Apple Watch Series 6

Device Family:  Apple Watch Version:  Dexcom G6 app watchOS 7.3.2 ||Dexcom Follow app watchOS 7.3.2 Device Enabled: 

Why am I being asked to update my phone’s operating system (OS) to continue getting Dexcom Follow app updates?

FAQs Main Categories:  Follow App for Family & Friends FAQs Sub Categories:  Troubleshooting Language US - English LBL Number:  LBL021023 Rev001 When an OS you’re using is no longer supported for your Dexcom Follow app, we will ask you to update your OS to continue getting app updates.…

Dexcom and Nick Jonas Unveil First-Ever Super Bowl Commercial

Language US - English Dexcom debuted their first ever Super Bowl commercial which calls for better care for people with diabetes who are still painfully pricking their fingers to measure their glucose levels.February2021Learn More
Show more

Dexcom Frequently Asked Questions

  • When was Dexcom founded?

    Dexcom was founded in 1999.

  • Who are Dexcom key executives?

    Dexcom's key executives are Kevin Sayer, Quentin Blackford and Donald Abbey.

  • How many employees does Dexcom have?

    Dexcom has 3,900 employees.

  • What is Dexcom revenue?

    Latest Dexcom annual revenue is $1.9 b.

  • What is Dexcom revenue per employee?

    Latest Dexcom revenue per employee is $494 k.

  • Who are Dexcom competitors?

    Competitors of Dexcom include LifeScan, Roche and Medtronic.

  • Where is Dexcom headquarters?

    Dexcom headquarters is located at 6340 Sequence Dr, San Diego.

  • Where are Dexcom offices?

    Dexcom has offices in San Diego, Brunn am Gebirge, Burnaby, Mainz and in 2 other locations.

  • How many offices does Dexcom have?

    Dexcom has 6 offices.